[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334373-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334373-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","nanocarrier-mediated-cancer-therapy-with-cisplatin-a-meta-analysis-with-a-promising-new-paradigm","Nanocarrier-mediated cancer therapy with cisplatin - A meta-analysis with a promising new paradigm","","Cisplatin is an established frontline chemotherapy, but its clinical limitations—side effects, metabolic deficiencies, and metastasis—create strong demand for safer next-generation formulations. This study evaluates whether nanocarriers improve cisplatin delivery in preclinical cancer models by synthesizing data from 94 eligible articles identified via PubMed and analyzed using Review Manager. Nanocarrier-encapsulated cisplatin shows versatile anticancer performance with statistically significant reductions in cancer cell viability, IC50, tumour volume, and platinum biodistribution to kidney and tumours, suggesting promise for future therapy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/nanocarrier-mediated-cancer-therapy-with-cisplatin-a-meta-analysis-with-a-promising-new-paradigm/334373/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/nanocarrier-mediated-cancer-therapy-with-cisplatin-a-meta-analysis-with-a-promising-new-paradigm/334373.png","ImageObject",300,407,{"name":42,"@type":43},"Aurelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study address regarding cisplatin therapy?","Question",{"text":63,"@type":64},"Cisplatin’s clinical use is limited by side effects and toxicity, along with challenges such as inadequate suppression of tumorigenesis and issues like chemoresistance. The study targets the need for improved formulations that reduce harm while maintaining anticancer efficacy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the meta-analysis conducted?",{"text":68,"@type":64},"The PubMed database was searched, 242 research articles were screened, and 94 articles met the selection criteria published up to December 31, 2023. The extracted data were synthesized using Review Manager software.",{"name":70,"@type":61,"acceptedAnswer":71},"What outcomes improve with nanocarrier-mediated cisplatin compared with free drug?",{"text":72,"@type":64},"Nanomedicine encapsulation using nanocarriers shows diminished cancer cell viability and related measures, including half maximal inhibitory concentration and tumour volume. It also reports changes in platinum biodistribution, including reduced kidney biodistribution and improved tumour targeting.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334373,1790013003,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Heliyon 10 (2024) e28171  \nContents lists available at ScienceDirect  \nHeliyon  \njournal [homepage:](homepage: www.cell.com/heliyon)[ www.cell.com/heliyon](homepage: www.cell.com/heliyon)  \n| Research article\u003Cbr>Nanocarrier-mediated cancer therapy with cisplatin: A meta-analysis with a promising new paradigm |  | |\n| --- | --- | --- |\n| Ranmali Ranasinghea, *, Michael Mathai a, Mohammed Abdullah Alshawshb, c, Anthony Zullia\u003Cbr>a Institute for Health and Sport, College of Health and Medicine, Victoria University, Melbourne, Victoria, Australia\u003Cbr>b Department of Paediatrics, School of Clinical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, 246 Clayton Road, Clayton, VIC, 3168, Australia\u003Cbr>c Department of Pharmacology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, 50603, Malaysia |  |  |\n| A R T I C L E I N F O\u003Cbr>Keywords: Cisplatin Nanocarriers\u003Cbr>Nanotechnology\u003Cbr>Nanomedicine Meta-analysis Cancer cell viability Tumour volume IC50\u003Cbr>Biodistribution of platinum in vital organs | A B S T R A C T\u003Cbr>Aims: Cisplatin is a frontline chemotherapeutic utilized to attenuate multiple cancers in the clinic. Given its side-effects, a new cisplatin formulation which could prevent cytotoxicity, metabolic deficiencies and metastasis is much needed. This study investigates whether nanocarriers can provide a better mode of drug delivery in preclinical cancer models seeking a potent anticancer therapeutic agent.\u003Cbr>Materials and methods: The PubMed database was searched, and 242 research articles were screened from which 94 articles qualified for selection from those published by December 31, 2023 and the data was synthesized using the Review Manager software.\u003Cbr>Key findings: Cisplatin encapsulated as a nanomedicine confirmed the versatility of nanocarriers insignificantly diminishing cancer cell viability, half maximal inhibitory concentration, tumour volume, biodistribution of platinum in tumours and kidney; atp \u003C 0.00001 and a 95% confidence interval.\u003Cbr>Significance: An estimated 19.3 million global cancer incidence is reported with 50% mortality worldwide for which nanocarrier-mediated cisplatin therapy is most promising. Our findings offer new vistas for future cancer treatment when combined with chemo-immunotherapy that utilizes the recently advanced nanozymes. |  |\n\nP L A I N L A N G U A G E  \nS U M M A R Y  \nNanocarriers versus free drug therapy in cancer resolution: Cisplatin is a widely used cancer medication for regulating and resolving tumour progression. It is still the choice of clinicians for treating many types of cancer although it causes severe side effects. Weight loss is a prominent  \n* Corresponding author.  \nE-mail address: [s4206095@live.vu.edu.au](s4206095@live.vu.edu.au) (R. Ranasinghe).  \n[https://doi.org/10.1016/j.heliyon.2024.e28171](https://doi.org/10.1016/j.heliyon.2024.e28171)  \nReceived 25 August 2023; Received in revised form 13 March 2024; Accepted 13 March 2024 Available online 27 March 2024  \n2405-8440/© 2024 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)).  \nR. Ranasinghe et al. Heliyon 10 (2024) e28171  \ndrawback for prescribing cisplatin, induced by loss of appetite, impaired digestion and nausea. Another major problem associated with cisplatin usage is toxicity in the kidneys that would need more drugs for containing not only the cancers but also kidney dysfunction.  \nThirdly, a recent growing concern is the patients developing resistance to cisplatin therapy. No alternatives have been found as remedial treatment for cisplatin’s negative outcomes yet. Nanocarriers have been shown to successfully control cancer by delivering cisplatin directly to the tumour site in mouse models, and we have evaluated their potential benefits ina meta-analysis for the first time. Our parameters in assessing nanocarrierentrapped cisplatin vers","cbCaieAQnWoTJzrA","https://ap.wps.com/l/cbCaieAQnWoTJzrA","pdf",30280555,39,"English","# Abstract\n## Aims\n## Materials and methods\n## Key findings\n## Significance\n# Introduction\n## Background","[{\"question\":\"What problem does the study address regarding cisplatin therapy?\",\"answer\":\"Cisplatin’s clinical use is limited by side effects and toxicity, along with challenges such as inadequate suppression of tumorigenesis and issues like chemoresistance. The study targets the need for improved formulations that reduce harm while maintaining anticancer efficacy.\"},{\"question\":\"How was the meta-analysis conducted?\",\"answer\":\"The PubMed database was searched, 242 research articles were screened, and 94 articles met the selection criteria published up to December 31, 2023. The extracted data were synthesized using Review Manager software.\"},{\"question\":\"What outcomes improve with nanocarrier-mediated cisplatin compared with free drug?\",\"answer\":\"Nanomedicine encapsulation using nanocarriers shows diminished cancer cell viability and related measures, including half maximal inhibitory concentration and tumour volume. It also reports changes in platinum biodistribution, including reduced kidney biodistribution and improved tumour targeting.\"}]","Nanocarrier-mediated cancer therapy with cisplatin - A meta-analysis with a promising new paradigm | PDF",1790006407,98]